Skip Navigation


NDT Advance Access originally published online on November 25, 2008
Nephrology Dialysis Transplantation 2009 24(1):38-42; doi:10.1093/ndt/gfn642
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
24/1/38    most recent
gfn642v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mann, J. F. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mann, J. F. E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org


What's new in hypertension 2008?

Johannes F. E. Mann

Munich General Hospitals, Ludwig Maximilians University Munchen and KfH Kidney Centre, Munich, Germany

Johannes F. E. Mann, Department of Nephrology and Hypertension, Schwabing General Hospital, LMU and KfH Kidney Center, Munchen, Germany. Tel: +49-89-3068-2386; Fax: +49-89-3068-3917; E-mail: johannes.mann@kms.mhn.de

Keywords: angiotensin; cardiovascular; pre-eclampsia; review; stroke

The first 150 words of the full text of this article appear below.



   Introduction
 
This editorial comment intends to inform readers of NDT about new information in the field of hypertension from mid-October 2007 to September 2008 that has not been published in nephrological journals. PubMed lists 2514 citations in the last 12 months with ‘hypertension’ as major topic including 353 reviews.



   Human studies
 
Antihypertensive drugs in people over 80 years of age
It is unclear whether we should treat hypertensive people above the age of 80 years with antihypertensive drugs. This hypertensive subgroup on the one hand is liable to adverse events of drug treatment and may die of many diseases unrelated to hypertension, but on the other hand the absolute cardiovascular risk increases dramatically with higher blood pressure. The HYVET study [1] randomized people above the age of 80 and with sustained systolic blood pressure >160 mmHg to placebo or to indapamid, 1.5 mg/day, to which perindopril, 2–4 mg/day, could be added if the target blood pressure of 150/80 was not . . . [Full Text of this Article]

Combining ACE inhibitors and angiotensin receptor blockers does not help
Should we screen asymptomatic people for carotid artery stenosis?
Obesity is not a lack of discipline
Subtle kidney damage first, hypertension later?
How to use ACE inhibitors and angiotensin receptor blockers with renal artery stenosis?


   Experimental studies
 
T-cells mediate angiotensin-induced hypertension and vascular damage
H-RAS oncogene associated with angiotensin-dependent hypertension
Unravelling pre-eclampsia
Activation of the renin–angiotensin system in diabetes is driven by hyperglycaemia
Hypertension is driving cellular senescence

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?